Can we predict the outcomes of national colorectal cancer screening and can predictions help us plan?

Gastroenterology

Volumn 129, Issue 4, 2005, Pages 1339-1342

  Seeff, Laura C ^a   Tangka, Florence K L ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

CANCER DIAGNOSIS; CANCER SCREENING; COLORECTAL CANCER; COMPUTED TOMOGRAPHIC COLONOGRAPHY; COST BENEFIT ANALYSIS; DNA DETERMINATION; EDITORIAL; ENDOSCOPY; HEALTH CARE; MEDICARE; OCCULT BLOOD TEST; PREDICTION; PRIORITY JOURNAL; REIMBURSEMENT; SIGMOIDOSCOPY;

EID: 26844439625     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2005.08.048     Document Type: Editorial

References (27)

1. Centers for Disease Control and Prevention Colorectal cancer test use among persons aged <50 years-United States, 2001 MMWR Morb Mortal Wkly Rep 52 2003 193 196
2. L.C. Seeff, M.R. Nadel, C. Klabunde, T. Thompson, J.A. Shapiro, S.W. Vernon, R.J. Coates Patterns and predictors of colorectal cancer test use in the adult US population Cancer 100 2004 2093 2103
3. U. Ladabaum, K. Song Projected national impact of colorectal cancer screening on clinical and economic outcomes and health services demand Gastroenterology 129 2005 1151 1163
4. K. Song, A.M. Fendrick, U. Ladabaum Fecal DNA testing compared to conventional colorectal cancer screening methods a decision analysis Gastroenterology 126 2004 1270 1279
5. U. Ladabaum, K. Song, A.M. Fendrick Colorectal neoplasia screening with virtual colonoscopy when, at what cost, and with what national impact? Clin Gastroenterol Hepatol 2 2004 554 563
6. U. Ladabaum, C.L. Chopra, G. Huang, J.M. Scheiman, M.E. Chernew, A.M. Fendrick Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis Ann Intern Med 135 2001 769 781
7. U. Ladabaum, J.M. Scheiman, A.M. Fendrick Potential effect of cyclooxgenase-2-specific inhibitors on the prevention of colorectal cancer a cost effectiveness analysis Am J Med 114 2003 546 554
8. S. Syngal, D. Chung, C. Willet, D. Schoetz, P. Schroy, E. Stoffel, D. Jagadeesh, K. Morel, M. Ross The loss of stool DNA mutation abnormalities in colorectal neoplasia after treatment Gastroenterology 124 2003 A5
9. L.C. Seeff, T.B. Richards, J.A. Shapiro, M.R. Nadel, D.L. Manninen, L.S. Given, F.B. Dong, L.D. Winges, M.T. McKenna How many endoscopies are performed for colorectal cancer screening? Results from CDC's survey of endoscopic capacity Gastroenterology 127 2004 1670 1677
10. J.S. Mandel, T.R. Church, J.H. Bond, F. Ederer, M.S. Geisser, S.J. Mongin, D.C. Snover, L.M. Schuman The effect of fecal occult-blood screening on the incidence of colorectal cancer N Engl J Med 343 2000 1603 1607
11. J.S. Mandel, J.H. Bond, T.R. Church Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study N Engl J Med 328 1993 1365 1371
12. J.V. Selby, G.D. Friedman, C.P. Quesenberry Jr, N.S. Weiss A case-control study of screening sigmoidoscopy and mortality from colorectal cancer N Engl J Med 326 1992 653 657
13. P.A. Newcomb, R.G. Norfleet, B.E. Storer, T.S. Surawicz, P.M. Marcus Screening sigmoidoscopy and colorectal cancer mortality J Natl Cancer Inst 84 1992 1572 1575
14. J.D. Hardcastle, J.O. Chamberlain, M.H. Robinson, S.M. Moss, S.S. Amar, T.W. Balfour, P.D. James, C.M. Mangham Randomised controlled trial of faecal-occult-blood screening for colorectal cancer Lancet 348 1996 1472 1477
15. O. Kronborg, C. Fenger, J. Olsen, O.D. Jorgensen, O. Sondergaard Randomised study of screening for colorectal cancer with faecal-occult-blood test Lancet 348 1996 1467 1471
16. L.C. Seeff, D. Manninen, F. Dong, S.K. Chattapodhyay, M.R. Nadel, F. Tangka, N. Molinari Is there endoscopic capacity to provide colorectal cancer screening to the unscreened population in the United States? Gastroenterology 127 2004 1661 1669
17. D. Schrag, J. Weeks Costs and cost-effectiveness of colorectal cancer prevention and therapy Semin Oncol 26 1999 561 568
18. Centers for Medicare & Medicaid Services. HCPC: Step 1. Available at: http://www.cms.hhs.gov/physicians/mpfsapp/step1.asp Accessed August 18, 2005
19. Centers for Medicare and Medicaid Services. CMS files for download for Medicare payment systems. Available at: http://www.cms.hhs.gov/providers/ pufdownload/default.asp#labfee Accessed August 18, 2005
20. U.S. Preventive Services Task Force. Screening for Colorectal Cancer: Recommendations and Rationale. July 2002. Agency for Healthcare Research and Quality, Rockville, MD. Available at: http://www.ahrq.gov/clinic/3rduspstf/ colorectal/colorr.htm Accessed August 24, 2005.
21. S.J. Winawer, R.H. Fletcher, D. Rex Colorectal cancer screening and surveillance clinical guidelines and rationale - updated based on new evidence Gastroenterology 124 2003 544 560
22. R.A. Smith, A.C. von Eschenbach, R. Wender American Cancer Society guidelines for the early detection of cancer update of early detection guidelines for prostate, colorectal, and endometrial cancers CA Cancer J Clin 51 2001 38 75
23. U.S. Census Bureau. Census 2000 summary file 1; 1990 census population, general population characteristics, United States (1990 CP-1-1), a trend expected to continue as the population ages and life expectancies increase.
24. J. Day Population Projections of the United States by Age, Sex, Race, and Hispanic Origin 1995 to 2050, U.S. Bureau of the Census, Current Population Reports, P25-1130 1996 U.S. Government Printing Office Washington, DC
25. New York State Department of Health. New York State cancer services. Available at: http://www.health.state.ny.us/nysdoh/cancer/center/ cancer_services.htm. Accessed August 19, 2005.
26. A.M. Palitz, J.V. Selby, S. Grossman, L.J. Finkler, M. Bevc, C. Kehr, C.A. Conell The Colon Cancer Prevention Program (CoCaP) rationale, implementation, and preliminary results HMO Pract 11 1997 5 12
27. U.S. Government Printing Office (GPO Access). Federal Register: http://frwebgate.access.gpo.gov/cgi-bin/multidb.cgi. Accessed August 25, 2005.